BioCentury
ARTICLE | Company News

Bradley, Quintiles deal

June 14, 2004 7:00 AM UTC

BDY will acquire dermatology company Bioglan Pharmaceuticals Co. (Malvern, Penn.) for $183 million. Bioglan, which is a wholly owned subsidiary of QTRN, posted sales of $55 million for the year ended April 30, 2004. Bioglan markets topical Solaraze diclofenac to treat actinic keratosis, Adoxa doxycycline, an oral antibiotic to treat acne, topical Zonalon doxepin to treat pruritus and Tx Systems, a line of topical treatments used during in-office procedures. BDY's Doak Dermatologics division markets products to treat acne, rosacea, seborrheic dermatitis and other skin conditions. ...